Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 8/20 | 0.56 |
| ▸ | WNT3A | P56704 | 8/20 | 0.56 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427249 | 1.00 | CTNNB1 (0.56) | CTNNB1WNT3AHTR1BHPGDSMN1; SMN2 | |
| SCHEMBL14757925 | 0.87 | CTNNB1 (0.73) | CTNNB1WNT3AHTR1BHPGDSMN1; SMN2 | |
| SCHEMBL30427297 | 0.87 | CTNNB1 (0.73) | CTNNB1WNT3AHTR1BHPGDSMN1; SMN2 | |
| SCHEMBL30427164 | 0.87 | HTR1B (0.55) | CTNNB1WNT3AHTR1BSMN1; SMN2L3MBTL1 | |
| SCHEMBL14135299 | 0.87 | HTR1B (0.55) | CTNNB1WNT3AHTR1BSMN1; SMN2L3MBTL1 | |
| SCHEMBL24111640 | 0.80 | HTR1B (0.52) | CTNNB1WNT3AHTR1BHTR3EHTR3B | |
| SCHEMBL24111708 | 0.79 | HTR1B (0.58) | CTNNB1WNT3AHTR1BHTR3EHTR3B | |
| SCHEMBL23330466 | 0.79 | CTNNB1 (0.40) | CTNNB1WNT3AHTR1BHPGDSMN1; SMN2 | |
| SCHEMBL26958041 | 0.79 | HSD17B3 (0.61) | HPGDSMN1; SMN2L3MBTL1HSD17B3NPC1 | |
| SCHEMBL103577 | 0.78 | HTR1B (0.59) | CTNNB1WNT3AHTR1BHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | TACTOGEN INC (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2023107653-A2 | BENZOFURAN SALT MORPHIC FORMS AND MIXTURES FOR THE TREATMENT OF MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107715-A1 | SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT | TACTOGEN INC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| CN-116075300-A | Advantageous benzofuran compositions for mental disorders or mental enhancement | 泰科根公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2021252538-A2 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2021-12-16 | — | — | WO | disclosed |
| US-8507680-B2 | Production process of a heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20120142924-A1 | PRODUCTION PROCESS OF A HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | MITSUBISHI RAYON CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8143407-B2 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| EP-1481978-B1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | MITSUBISHI RAYON CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100010224-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | MITSUBISHI RAYON CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-7612218-B2 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | MITSUBISHI RAYON CO., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1481978-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | Mitsubishi Rayon Co., Ltd. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767305-B2 | Advantageous benzofuran compositions for mental disorders or enhancement | BDNF, CREBBP, ELF3 | CTNNB1 2504/4885WNT3A 3773/4885HTR1B 273/4885 |
| US-20230150963-A1 | ADVANTAGEOUS BENZOFURAN COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT | BDNF, CREBBP, ELF3 | CTNNB1 2504/4885WNT3A 3773/4885HTR1B 273/4885 |
| US-20100010224-A1 | PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | PIN4, IPO5, HLCS | CTNNB1 3662/4885WNT3A 1951/4885HTR1B 3539/4885 |
| US-20120142924-A1 | PRODUCTION PROCESS OF A HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST | PIN4, NISCH, HLCS | CTNNB1 3056/4885WNT3A 1261/4885HTR1B 3596/4885 |
| US-20050148775-A1 | Process for production of heteroaryl-type boron compounds with iridium catalyst | PIN4, IPO5, HLCS | CTNNB1 3662/4885WNT3A 1951/4885HTR1B 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.